
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc. exhibits a positive financial outlook driven by an increase in projected risk-adjusted sales, which are anticipated to rise from $171 million in 2026 to a peak of $1.9 billion by 2031. The successful completion of the ROSELLA trial and subsequent FDA approval for relacorilant enhances the company's market penetration estimate to 25%, underlining its competitive edge in ovarian cancer treatments. With a planned launch supported by a dedicated oncology sales force and a favorable clinical profile positioning relacorilant as a potential preferred therapy, there remains significant potential for growth in oncology indications not yet included in current valuations.
Bears say
Corcept Therapeutics Inc. faces a negative outlook primarily due to significant valuation adjustments, with the 12-month price target reduced from $105 to $67 per diluted share, reflecting concerns over revenue projections and increased pricing pressure on Korlym. The Complete Response Letter for relacorilant has led to a marked decline in share prices, raising concerns about management turnover potentially disrupting clinical developments and impacting future sales. Furthermore, the anticipated increase in discounts for Korlym, reaching as high as 50% by 2032, coupled with heightened execution risks, underscores the challenging landscape facing the company's financial performance.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares